Gemigliptin/Dapagliflozin

吉格列汀/达格列净

Report date: 2026/03/30 17:02:26

Base Information

Drug NameGemigliptin/Dapagliflozin
Drug Alias NameZemidapa
ClassificationSmall molecules
Mechanisms of ActionSodium/glucose cotransporter 2 inhibitorsProtein kinase AMP-activated non-catalytic subunit beta 1 activatorsDipeptidyl peptidase IV inhibitors
TargetsProtein kinase AMP-activated non-catalytic subunit beta 1Sodium/glucose cotransporter 2Dipeptidyl peptidase IV
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2022/06/21
Country/TerritorySouth Korea
CombinationsYes Dapagliflozin Propanediol MonohydrateGemigliptin L-tartrate Sesquihydrate
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesLg Chemical Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLg Chemical Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A